SG11202000230VA - Carboxamides as modulators of sodium channels - Google Patents
Carboxamides as modulators of sodium channelsInfo
- Publication number
- SG11202000230VA SG11202000230VA SG11202000230VA SG11202000230VA SG11202000230VA SG 11202000230V A SG11202000230V A SG 11202000230VA SG 11202000230V A SG11202000230V A SG 11202000230VA SG 11202000230V A SG11202000230V A SG 11202000230VA SG 11202000230V A SG11202000230V A SG 11202000230VA
- Authority
- SG
- Singapore
- Prior art keywords
- carboxamides
- modulators
- sodium channels
- channels
- sodium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762531313P | 2017-07-11 | 2017-07-11 | |
US201762608283P | 2017-12-20 | 2017-12-20 | |
PCT/US2018/041649 WO2019014352A1 (fr) | 2017-07-11 | 2018-07-11 | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000230VA true SG11202000230VA (en) | 2020-02-27 |
Family
ID=63036498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000230VA SG11202000230VA (en) | 2017-07-11 | 2018-07-11 | Carboxamides as modulators of sodium channels |
Country Status (23)
Country | Link |
---|---|
US (3) | US10647661B2 (fr) |
EP (1) | EP3651752A1 (fr) |
JP (1) | JP7277431B2 (fr) |
KR (1) | KR20200026987A (fr) |
CN (1) | CN111065383A (fr) |
AU (1) | AU2018300150A1 (fr) |
BR (1) | BR112020000553A2 (fr) |
CA (1) | CA3069720A1 (fr) |
CL (1) | CL2020000075A1 (fr) |
CO (1) | CO2020000145A2 (fr) |
CR (1) | CR20200064A (fr) |
DO (1) | DOP2020000004A (fr) |
EC (1) | ECSP20003147A (fr) |
IL (1) | IL271948A (fr) |
JO (1) | JOP20200001A1 (fr) |
MA (1) | MA49566A (fr) |
PE (1) | PE20201164A1 (fr) |
PH (1) | PH12020500066A1 (fr) |
SG (1) | SG11202000230VA (fr) |
TN (1) | TN2020000001A1 (fr) |
TW (1) | TW201920081A (fr) |
UY (1) | UY37806A (fr) |
WO (1) | WO2019014352A1 (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3239134T1 (sl) | 2013-01-31 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Piridon amidi kot modulatorji natrijevih kanalov |
HUE037876T2 (hu) | 2013-07-19 | 2018-09-28 | Vertex Pharma | Szulfonamidok mint nátriumcsatorna-modulátorok |
SG10201913313QA (en) | 2013-12-13 | 2020-03-30 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
EP3625214B1 (fr) | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Amides de pyridone deutérés et leurs promédicaments utilisés en tant que modulateurs de canaux sodiques |
JP7277431B2 (ja) | 2017-07-11 | 2023-05-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのカルボキサミド |
AU2019218387A1 (en) | 2018-02-12 | 2020-08-27 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
PL3752510T3 (pl) | 2018-02-15 | 2023-05-08 | Vertex Pharmaceuticals Incorporated | Makrocykle jako modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa, ich kompozycje farmaceutyczne, ich zastosowanie w leczeniu mukowiscydozy oraz proces ich wytwarzania |
KR20210019119A (ko) | 2018-07-09 | 2021-02-19 | 리버 인스티튜트, 아이엔씨 | Nav1.8을 억제하기 위한 피리다진(PYRIDAZINE) 화합물 |
JP2021530478A (ja) * | 2018-07-09 | 2021-11-11 | リーバー インスティチュート インコーポレイテッドLieber Institute, Inc. | NaV1.8を阻害するためのピリジンカルボキシアミド化合物 |
US20210387966A1 (en) * | 2018-11-02 | 2021-12-16 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
WO2020146682A1 (fr) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides utilisés en tant que modulateurs de canaux sodiques |
US20220110923A1 (en) * | 2019-01-10 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
TW202043200A (zh) * | 2019-01-25 | 2020-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 2-側氧基-1,2-二氫吡啶類衍生物、其製備方法及其在醫藥上的應用 |
WO2020176763A1 (fr) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8 |
WO2020219867A1 (fr) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur |
CN114599657A (zh) | 2019-08-14 | 2022-06-07 | 弗特克斯药品有限公司 | Cftr调节剂的结晶形式 |
TW202115038A (zh) * | 2019-08-19 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用 |
CA3150400A1 (fr) * | 2019-09-12 | 2021-03-18 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Oxynitrure de pyridine, son procede de preparation et son utilisation |
IL293592A (en) | 2019-12-06 | 2022-08-01 | Vertex Pharma | Transduced tetrahydrofurans as sodium channel modulators |
CN110950797A (zh) * | 2019-12-06 | 2020-04-03 | 丽水绿氟科技有限公司 | 一种2-三氟甲基-3-氟-4-吡啶甲酸及其衍生物的制备方法 |
CN110937994B (zh) * | 2019-12-10 | 2022-04-22 | 浙江大洋生物科技集团股份有限公司 | 二步氯化法合成2,4-二氯-6-氟苯甲酰氯的方法 |
CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
JP2023538713A (ja) | 2020-05-06 | 2023-09-11 | バイエル、アクチエンゲゼルシャフト | 殺真菌性化合物としてのピリジン(チオ)アミド |
US20230180756A1 (en) | 2020-05-12 | 2023-06-15 | Bayer Aktiengesellschaft | Triazine and pyrimidine (thio)amides as fungicidal compounds |
AR122628A1 (es) | 2020-06-17 | 2022-09-21 | Merck Sharp & Dohme | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8 |
CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
CN111920796A (zh) * | 2020-08-28 | 2020-11-13 | 南京医科大学 | 化合物在制备治疗癫痫药物中的应用 |
CN111808019B (zh) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
CN114031518B (zh) * | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
CA3211594A1 (fr) | 2021-03-11 | 2022-09-15 | Yong Zhang | Forme cristalline d'un compose d'oxyde d'azote de pyridine et son utilisation |
IL307338A (en) | 2021-04-05 | 2023-11-01 | Bristol Myers Squibb Co | Pyridinyl substituted oxisoisoindoline compounds for cancer therapy |
EP4334293A1 (fr) | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopipérazine carboxamides et cyclohétéroalkyle 3-oxopipérazine carboxamides en tant qu'inhibiteurs de nav1.8 |
JP2024522290A (ja) * | 2021-06-04 | 2024-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの置換テトラヒドロフラン調節因子の合成のためのプロセス |
JP2024520648A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としての置換テトラヒドロフラン-2-カルボキサミド |
CA3221939A1 (fr) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques |
CA3221960A1 (fr) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Tetrahydrofuranes a substitution hydroxy et (halo)alkoxy utiles en tant que modulateurs de canaux sodiques |
AU2022285758A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
MX2023014378A (es) | 2021-06-04 | 2023-12-15 | Vertex Pharma | N-(hidroxialquil(hetero)aril)tetrahidrofurano carboxamidas como moduladores de canales de sodio. |
EP4346818A1 (fr) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Formes galéniques solides et schémas posologiques comprenant du (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl)tétrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
AR126669A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
AR126670A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
WO2023138599A1 (fr) | 2022-01-18 | 2023-07-27 | 成都康弘药业集团股份有限公司 | Inhibiteur de nav1.8 à cycle condensé aromatique et son utilisation |
WO2023186102A1 (fr) * | 2022-04-02 | 2023-10-05 | 武汉人福创新药物研发中心有限公司 | Inhibiteur de nav1.8 et son utilisation |
WO2023205465A1 (fr) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryles pour le traitement de la douleur |
TW202404969A (zh) | 2022-04-22 | 2024-02-01 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (fr) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Composés hétéroaryle pour le traitement de la douleur |
WO2023211990A1 (fr) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Inhibiteurs d'amides hétérocycliques bicycliques de na v1.8 pour le traitement de la douleur |
CN116947713A (zh) * | 2022-04-25 | 2023-10-27 | 中国科学院上海药物研究所 | 并环类化合物及其应用 |
TW202413335A (zh) * | 2022-06-22 | 2024-04-01 | 大陸商武漢人福創新藥物研發中心有限公司 | Nav1.8抑制劑 |
WO2024041613A1 (fr) * | 2022-08-24 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | Composé hétérocyclique, son procédé de préparation et son utilisation pharmaceutique |
WO2024046253A1 (fr) * | 2022-08-28 | 2024-03-07 | 上海汇伦医药股份有限公司 | Régulateur de canal sodique et son utilisation |
WO2024046409A1 (fr) * | 2022-08-31 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | Composé hétérocyclique, son procédé de préparation et son utilisation pharmaceutique |
WO2024054622A2 (fr) * | 2022-09-09 | 2024-03-14 | Latigo Biotherapeutics, Inc. | Composés bloquant les canaux sodiques, leurs dérivés et leurs procédés d'utilisation |
WO2024123815A1 (fr) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Procédé de synthèse de modulateurs de tétrahydrofurane substitués de canaux sodiques |
WO2024146632A1 (fr) * | 2023-01-06 | 2024-07-11 | 西藏海思科制药有限公司 | Dérivé de tétrahydrothiophène et son utilisation en médecine |
WO2024153856A1 (fr) * | 2023-01-18 | 2024-07-25 | Orion Corporation | Procédé de préparation de 3- (4,5-dichloro-2-(4- (trifluorométhoxy)phénoxy)benzamido)pyridine 1-oxyde |
Family Cites Families (249)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1025305A (en) | 1910-07-29 | 1912-05-07 | Andrew Rasmussen | Feeding means for power hacksaw-machines. |
US1008714A (en) | 1910-12-27 | 1911-11-14 | Henry M Hammer | Delinting-machine. |
US2511231A (en) | 1949-03-26 | 1950-06-13 | Eastman Kodak Co | 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography |
US2688617A (en) | 1951-07-17 | 1954-09-07 | American Cyanamid Co | Sulfonated dihalogeno diaminostilbenes |
BE516025A (fr) | 1951-12-05 | |||
US2657134A (en) | 1951-12-05 | 1953-10-27 | Eastman Kodak Co | Photographic emulsion with colored couplers containing isophthalic ester groups |
US2725292A (en) | 1952-05-15 | 1955-11-29 | Eastman Kodak Co | Colored couplers containing solubilizing groups |
US2710802A (en) | 1953-03-16 | 1955-06-14 | Eastman Kodak Co | Dialkyl-5-(oxanilamido) isophthalate couplers for color photography |
US2710803A (en) | 1953-03-26 | 1955-06-14 | Eastman Kodak Co | Color couplers containing hydroxyalkyl groups |
BE528163A (fr) | 1953-04-17 | |||
BE531589A (fr) | 1953-09-02 | |||
US4218765A (en) | 1974-10-03 | 1980-08-19 | Standard Oil Company (Indiana) | Two-dimensional frequency domain filtering |
DE2623228C3 (de) | 1976-05-24 | 1981-09-10 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide |
US4639273A (en) | 1983-05-06 | 1987-01-27 | Morton Thiokol, Inc. | Asphalt-adhesion improving additives prepared by formaldehyde condensation with polyamines |
JPS63182182A (ja) | 1987-01-23 | 1988-07-27 | Fuji Photo Film Co Ltd | 感熱記録材料 |
FR2628864B1 (fr) | 1988-03-21 | 1990-06-15 | France Etat | Procede de segmentation d'un champ de vecteurs vitesse, notamment de vitesses de deplacement de points d'une image dans une sequence d'images |
KR920701167A (ko) | 1989-07-07 | 1992-08-11 | 에릭 에스. 딕커 | 약제학적 활성 화합물 |
JP2766323B2 (ja) | 1989-07-19 | 1998-06-18 | 株式会社東芝 | 表示調整装置 |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
DE4019307A1 (de) | 1990-06-16 | 1991-12-19 | Bayer Ag | 2-methoximinocarbonsaeureester |
US5258407A (en) | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5449691A (en) | 1991-12-31 | 1995-09-12 | Sterling Winthrop Inc. | 3,4-disubstituted anilines-immunomodulating agents |
FR2687932A1 (fr) | 1992-02-27 | 1993-09-03 | Oreal | Dispersion huile-dans-l'eau susceptible de former des films composites. |
JPH05313169A (ja) | 1992-05-08 | 1993-11-26 | Fuji Photo Film Co Ltd | 液晶配向膜 |
HUT63941A (en) | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
GB9408185D0 (en) | 1994-04-25 | 1994-06-15 | Fujisawa Pharmaceutical Co | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same |
AU687202B2 (en) | 1994-05-31 | 1998-02-19 | Teijin Limited | Naphthalene derivative |
US5532235A (en) | 1995-01-17 | 1996-07-02 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5536718A (en) | 1995-01-17 | 1996-07-16 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
AR002459A1 (es) | 1995-01-17 | 1998-03-25 | American Cyanamid Co | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. |
US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
DE19523640A1 (de) | 1995-06-29 | 1997-01-02 | Bayer Ag | Substituierte Carbonylaminophenyluracile |
DE19621522A1 (de) | 1996-05-29 | 1997-12-04 | Hoechst Schering Agrevo Gmbh | Neue N-Acylsulfonamide, neue Mischungen aus Herbiziden und Antidots und deren Verwendung |
JP3731963B2 (ja) | 1997-01-14 | 2006-01-05 | 株式会社シマノ | 釣り竿用口栓 |
JPH10213820A (ja) | 1997-01-31 | 1998-08-11 | Canon Inc | 液晶素子及び液晶装置 |
ATE248824T1 (de) | 1997-04-22 | 2003-09-15 | Neurosearch As | Substituierte phenylderivate, ihre herstellung und verwendung |
JP2002506873A (ja) | 1998-03-18 | 2002-03-05 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 複素環式シグナル伝達阻害剤、それを含む組成物 |
AU3665199A (en) | 1998-04-29 | 1999-11-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
JP2002179651A (ja) | 1998-06-19 | 2002-06-26 | Wakamoto Pharmaceut Co Ltd | ベンズアニリド誘導体及び医薬組成物 |
SK5222001A3 (en) | 1998-10-22 | 2002-05-09 | Neurosearch As | Substituted phenyl derivatives, their preparation and use |
PL351470A1 (en) | 1999-04-28 | 2003-04-22 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
WO2001007028A2 (fr) | 1999-07-23 | 2001-02-01 | Allergan Sales, Inc. | Utilisation d'antagonistes de recepteurs de retinoides dans le traitement du cancer de la prostate |
JP4744050B2 (ja) | 1999-09-17 | 2011-08-10 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ベンズアミドおよび関連するXa因子阻害剤 |
US6531291B1 (en) | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
US6313168B1 (en) | 1999-12-15 | 2001-11-06 | Allergan Sales, Inc. | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
US20030114482A1 (en) | 1999-12-15 | 2003-06-19 | Maurizio Pacifici | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
US20020065303A1 (en) | 2000-02-01 | 2002-05-30 | Bing-Yan Zhu | Bivalent phenylene inhibitors of factor Xa |
US6376515B2 (en) | 2000-02-29 | 2002-04-23 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor Xa |
WO2001066098A2 (fr) | 2000-03-09 | 2001-09-13 | Aventis Pharma Deutschland Gmbh | Utilisations therapeutiques des mediateurs ppar |
MY138097A (en) | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
US20020032238A1 (en) * | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
DE10033337A1 (de) | 2000-07-08 | 2002-01-17 | Boehringer Ingelheim Pharma | Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
MXPA03003002A (es) | 2000-10-05 | 2004-12-06 | Fujisawa Pharmaceutical Co | Compuestos de benzamina como inhibidores de la secrecion de la apo b. |
AU1339302A (en) | 2000-10-20 | 2002-05-06 | Biocryst Pharm Inc | Biaryl compounds as serine protease inhibitors |
EP1332131A2 (fr) | 2000-11-07 | 2003-08-06 | Bristol-Myers Squibb Company | Derives d'acide utiles comme inhibiteurs de serines proteases |
AU2002224115A1 (en) | 2000-11-28 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | 1,4,5,6-tetrahydroimidazo(4,5-d)diazepine derivatives or salts thereof |
AU3320602A (en) | 2000-12-06 | 2002-06-18 | Aventis Pharma Gmbh | Guanidine and amidine derivatives as factor xa inhibitors |
EP1344525A4 (fr) | 2000-12-22 | 2005-05-25 | Ishihara Sangyo Kaisha | Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives |
EP1217000A1 (fr) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibiteurs du factor Xa et factor VIIa |
WO2002054077A2 (fr) | 2000-12-29 | 2002-07-11 | 7Tm Pharma A/S | Validation de molecules biologiques en tant que cibles de medicaments au moyen de chelates d'ions metalliques chez des modeles d'animaux de laboratoire |
WO2002070483A1 (fr) | 2001-03-05 | 2002-09-12 | E. I. Du Pont De Nemours And Company | Agents heterocycliques diamide de lutte contre des parasites invertebres |
DE60139510D1 (de) | 2001-04-06 | 2009-09-17 | Biocryst Pharm Inc | Biarylverbindungen als serinproteaseinhibitoren |
WO2002090347A1 (fr) | 2001-04-30 | 2002-11-14 | Fujisawa Pharmaceutical Co., Ltd. | Composes biarylcarboxamide comme inhibiteurs d'apolipoproteine b |
WO2002098839A1 (fr) | 2001-06-01 | 2002-12-12 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamides et procede de preparation de ceux-ci |
AU2002312370A1 (en) | 2001-06-13 | 2002-12-23 | Roland W. Burli | Antipathogenic benzamide compounds |
WO2003003008A1 (fr) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Bibliotheques chimiques utiles aux procedes de decouvertes de medicaments |
WO2003003009A1 (fr) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Utilisation de chelates a ions metalliques dans la validation de molecules biologiques utilisees comme cibles medicamenteuses dans des modeles animaux experimentaux |
DE10132686A1 (de) | 2001-07-05 | 2003-01-16 | Boehringer Ingelheim Pharma | Heteroarylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
WO2003013516A1 (fr) | 2001-08-10 | 2003-02-20 | Adipogenix, Inc. | Composes servant a moduler l'accumulation des graisses |
AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
US20050038035A1 (en) | 2001-11-28 | 2005-02-17 | Hisashi Takasugi | Heterocyclic amide compounds as apolipoprotein b inhibitors |
WO2003055477A1 (fr) | 2001-12-21 | 2003-07-10 | 7Tm Pharma A/S | Methode de traitement de troubles lies au recepteur de la melanocortine (mc), faisant intervenir un chelate et/ou un chelateur |
CA2471566A1 (fr) | 2002-01-10 | 2003-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combinaison d'inhibiteurs de mtp ou d'inhibiteurs de secretions apob avec des fibrates en vue d'une utilisation comme medicament |
CN1620449A (zh) | 2002-01-22 | 2005-05-25 | 纳幕尔杜邦公司 | 二酰胺化合物无脊椎害虫防治剂 |
BR0306292A (pt) | 2002-02-28 | 2004-08-24 | Japan Tobacco Inc | Composto de éster e uso medicinal do mesmo |
NZ535614A (en) | 2002-03-11 | 2006-10-27 | Tibotec Pharm Ltd | Small molecule entry inhibitors |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
JP2003342175A (ja) | 2002-05-24 | 2003-12-03 | Yamanouchi Pharmaceut Co Ltd | 新規なベンゾアゼピン誘導体又はその塩を有効成分とするメニエール病治療剤 |
JP2004043456A (ja) | 2002-05-24 | 2004-02-12 | Yamanouchi Pharmaceut Co Ltd | ベンゾアゼピン誘導体又はその塩を有効成分とする医薬 |
US20040082627A1 (en) | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
JP2005535710A (ja) | 2002-08-09 | 2005-11-24 | トランス テック ファーマ,インコーポレイテッド | アリールおよびヘテロアリール化合物ならびに凝固を調節する方法 |
US20040110802A1 (en) | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
JP2004175739A (ja) | 2002-11-28 | 2004-06-24 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
BR0316607B1 (pt) | 2002-12-12 | 2014-12-23 | Ciba Sc Holding Ag | Derivados de hidroxifenil benzofenona substituídos com amino, seu uso, e preparação cosmética. |
CA2505604A1 (fr) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Inhibiteurs de proteine microsomale de transfert de triglyceride |
KR101076018B1 (ko) | 2003-01-08 | 2011-10-21 | 유니버시티 오브 워싱톤 | 항균제 |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
JP2004315395A (ja) | 2003-04-14 | 2004-11-11 | Yamanouchi Pharmaceut Co Ltd | 新規な安息香酸誘導体又はその塩 |
WO2005000309A2 (fr) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Composes chimiques |
AU2004270733B2 (en) | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
EP1669348A4 (fr) | 2003-09-30 | 2009-03-11 | Eisai R&D Man Co Ltd | Agent antifongique a compose heterocyclique |
WO2005040135A1 (fr) | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | Medicament antistress et usage medical correspondant |
BR122015027139B1 (pt) | 2004-01-28 | 2016-05-10 | Mitsui Chemicals Inc | compostos derivados de amida, inseticida compreendendo os mesmos e método de uso dos mesmos como inseticida |
DE102004009238A1 (de) | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
US7427390B2 (en) | 2004-03-10 | 2008-09-23 | Schering Ag | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy |
WO2006007864A1 (fr) | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Traitement d'etats neurodegeneratifs |
BRPI0513717A (pt) | 2004-07-23 | 2008-05-13 | Pfizer | derivados de piridina |
DE102004050196A1 (de) | 2004-10-15 | 2006-04-20 | Sanofi-Aventis Deutschland Gmbh | Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
EP1819330A1 (fr) | 2004-12-01 | 2007-08-22 | Devgen N.V. | Dérivés de thiazole substitués en position 5 par carboxamide, interagissant avec les canaux potassium dépendants de la famille kv |
TW200635899A (en) | 2004-12-22 | 2006-10-16 | Astrazeneca Ab | Chemical compounds |
WO2006068199A1 (fr) | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | Dérivés de 3-oxy-1,2,4-triazole métaboliquement stables |
JP5149003B2 (ja) | 2005-06-21 | 2013-02-20 | 三井化学アグロ株式会社 | アミド誘導体ならびに該化合物を含有する殺虫剤 |
MX2007016070A (es) | 2005-07-07 | 2008-03-10 | Abbott Lab | Promotores de apoptosis. |
JP4580836B2 (ja) | 2005-07-25 | 2010-11-17 | 三井化学アグロ株式会社 | 殺虫殺菌組成物 |
CA2621406A1 (fr) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Composes actifs sur les ppar |
US20070219192A1 (en) | 2005-11-02 | 2007-09-20 | Xiangping Qian | Certain chemical entities, compositions, and methods |
WO2007052843A1 (fr) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | Compose amide heterocyclique et son utilisation |
EP1966184B1 (fr) | 2005-12-20 | 2010-08-25 | NeuroSearch A/S | Derives de pyridinyl-quinazoline et leur utilisation medicale |
UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
US7351434B2 (en) | 2006-04-07 | 2008-04-01 | Academia Sinica | Therapeutic Gastrodia extracts |
NZ596413A (en) | 2006-04-11 | 2013-03-28 | Vertex Pharma | Phenyl-sulfinyl-sulfamoylphenyl-benzamide derivatives that inhibit voltage-gated sodium channels |
EP2073806B1 (fr) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Utilisation de composés de spiro-oxindole comme agents thérapeutiques |
WO2008044767A1 (fr) | 2006-10-13 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Dérivé d'amine aromatique et utilisation de celui-ci |
JP2008106017A (ja) | 2006-10-27 | 2008-05-08 | Tokyo Univ Of Science | Oatp選択的阻害性を有する化合物、及び該化合物を含むoatpの選択的阻害剤 |
CN105193799A (zh) | 2006-12-08 | 2015-12-30 | 米伦纽姆医药公司 | 使用经口因子xa抑制剂治疗血栓形成的单位剂量调配物和方法 |
GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
JP4325681B2 (ja) | 2007-02-13 | 2009-09-02 | ソニー株式会社 | 固体撮像装置、撮像装置 |
WO2008104994A2 (fr) | 2007-02-28 | 2008-09-04 | Advinus Therapeutics Private Limited | Dérivés d'acétamide 2,2,2-tri-substitué en tant qu'activateurs de la glucokinase, leur procédé de préparation et leur application pharmaceutique |
ES2398606T3 (es) | 2007-05-03 | 2013-03-20 | Pfizer Limited | Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio |
WO2008140810A1 (fr) | 2007-05-11 | 2008-11-20 | Cytokinetics, Incorporated | Certaines entités chimiques, compositions et procédés |
WO2008156783A2 (fr) | 2007-06-18 | 2008-12-24 | University Of Louisville Research Foundation, Inc. | Famille d'inhibiteurs de pfkfb3 à activités anti-néoplasiques |
BRPI0813271A2 (pt) | 2007-06-26 | 2014-12-30 | Sanofi Aventis | Síntese regiosseletiva catalisada por cobre de benzimidazóis e azabenzimidazóis |
US20090012091A1 (en) | 2007-07-02 | 2009-01-08 | Kinagen, Inc. | Oximide derivatives and their therapeutical application |
CN101952269B (zh) | 2007-10-10 | 2014-06-25 | 巴斯夫欧洲公司 | 锍盐引发剂 |
JP5473921B2 (ja) | 2007-10-10 | 2014-04-16 | ビーエーエスエフ ソシエタス・ヨーロピア | スルホニウム塩開始剤 |
NZ584519A (en) * | 2007-10-11 | 2012-07-27 | Vertex Pharma | Aryl amides useful as inhibitors of voltage-gated sodium channels |
NZ584475A (en) | 2007-10-11 | 2012-07-27 | Vertex Pharma | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
CA2701766A1 (fr) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides utiles en tant qu'inhibiteurs de canaux sodiques sensibles au voltage |
JP2009108152A (ja) | 2007-10-29 | 2009-05-21 | Sumitomo Chemical Co Ltd | 重合性化合物および光学フィルム |
WO2009070533A1 (fr) | 2007-11-29 | 2009-06-04 | Complegen, Inc. | Procédés d'inhibition de stéaroyle-coa désaturase |
JP2009149754A (ja) | 2007-12-20 | 2009-07-09 | Sumitomo Chemical Co Ltd | 重合性化合物および該重合性化合物を重合してなる光学フィルム |
CA2709784A1 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procede permettant de modifier la duree de vie d'organismes eucaryotes |
JP2009209090A (ja) | 2008-03-04 | 2009-09-17 | Mitsui Chemicals Inc | 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法 |
US20100009970A1 (en) | 2008-03-19 | 2010-01-14 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
JP5219583B2 (ja) | 2008-03-31 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルムとその製造方法、光学部材及び表示装置 |
JP2010001284A (ja) | 2008-05-20 | 2010-01-07 | Sumitomo Chemical Co Ltd | 化合物及び光学フィルム |
PL2959900T3 (pl) | 2008-06-16 | 2017-11-30 | University Of Tennessee Research Foundation | Związek do leczenia raka |
US8507491B2 (en) | 2008-08-25 | 2013-08-13 | Irm Llc | Compounds and compositions as hedgehog pathway inhibitors |
JP5443720B2 (ja) | 2008-09-05 | 2014-03-19 | 住友化学株式会社 | 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置 |
JP2010066630A (ja) | 2008-09-12 | 2010-03-25 | Sumitomo Chemical Co Ltd | 光学フィルムの製造方法及び光学フィルム |
JP5658157B2 (ja) | 2008-09-18 | 2015-01-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 置換ピロリジン−2−カルボキサミド |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
WO2010048149A2 (fr) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie |
JP5649779B2 (ja) | 2008-11-28 | 2015-01-07 | 住友化学株式会社 | 液晶性組成物及び光学フィルム |
MX2011006904A (es) | 2008-12-26 | 2011-07-20 | Dainippon Sumitomo Pharma Co | Compuesto heterociclico biciclico novedoso. |
CN101838264B (zh) | 2009-03-16 | 2014-12-03 | 住友化学株式会社 | 化合物、光学膜和光学膜的制造方法 |
JP5899607B2 (ja) | 2009-03-16 | 2016-04-06 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
EP2432556A1 (fr) | 2009-05-18 | 2012-03-28 | Orion Corporation | Inhibiteurs de protéase |
EP2253617A1 (fr) | 2009-05-20 | 2010-11-24 | Bayer CropScience AG | Composés halogénés comme pesticides |
WO2010138901A1 (fr) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Composés contenant de l'acide carboxylique, leurs dérivés et procédés d'utilisation associés |
JP2011006360A (ja) | 2009-06-26 | 2011-01-13 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
US8629149B2 (en) | 2009-09-04 | 2014-01-14 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
EP2477625A4 (fr) | 2009-09-14 | 2012-10-24 | Phusis Therapeutics Inc | Compositions et formulations pharmaceutiques comprenant des inhibiteurs du domaine d'homologie à la pleckstrine et leurs méthodes d'utilisation |
US8420647B2 (en) | 2010-01-21 | 2013-04-16 | Hoffmann-La Roche Inc. | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds |
JP5375644B2 (ja) | 2010-02-10 | 2013-12-25 | 住友化学株式会社 | 組成物及び光学フィルム |
AU2010347233B2 (en) | 2010-03-01 | 2015-06-18 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
US8895608B2 (en) | 2010-04-23 | 2014-11-25 | Kineta, Inc. | Sulfonamide anti-viral compounds |
EP2563759B1 (fr) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Composés qui modulent le calcium intracellulaire |
CA2812526A1 (fr) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Amides de chromene heterocyclique-piperidine spirocyclique utiles comme modulateurs des canaux ioniques |
WO2012016133A2 (fr) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53 |
CA2808841A1 (fr) | 2010-08-24 | 2012-03-01 | Brigham Young University | Composes antimetastatiques |
US20130225870A1 (en) | 2010-08-25 | 2013-08-29 | Synta Pharmaceuticals Corp. | Method of synthesizing substituted 2-alkyl phenols |
EP2651404B1 (fr) | 2010-12-14 | 2015-10-14 | Electrophoretics Limited | Inhibiteurs de caséine kinase 1 delta (ck1delta) |
TWI520964B (zh) | 2011-02-02 | 2016-02-11 | 維泰克斯製藥公司 | 作為離子通道調節劑之吡咯并吡-螺環哌啶醯胺 |
MX2013009393A (es) | 2011-02-18 | 2013-08-29 | Vertex Pharma | Piperidinamidas cromano-espirociclicas como moduladores de canales de iones. |
EP2681200A4 (fr) | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | Inhibiteurs de type benzimidazole du canal sodique |
CA2829803A1 (fr) | 2011-03-14 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | Amides de piperidine spirocycliques morpholines utilises en tant que modulateurs de canaux ioniques |
WO2012129562A2 (fr) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Composés et procédés pour l'induction de la chondrogenèse |
PT2713722T (pt) | 2011-05-31 | 2017-06-27 | Receptos Llc | Novos estabilizadores e moduladores do receptor glp-1 |
MX2013014326A (es) | 2011-06-20 | 2014-01-23 | Du Pont | Compuestos heterociclicos para tratar infecciones por helmintos. |
CA2839451A1 (fr) | 2011-06-27 | 2013-01-03 | The Jackson Laboratory | Procedes et compositions pour le traitement du cancer et d'une maladie auto-immune |
US9169246B2 (en) | 2011-09-26 | 2015-10-27 | Sanofi | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
ES2527188T3 (es) | 2011-09-26 | 2015-01-21 | Sanofi | Derivados de pirazolquinolinona, su preparación y su uso terapéutico |
CN103012397B (zh) | 2011-09-26 | 2017-03-01 | 赛诺菲 | 吡唑并喹啉酮衍生物、其制备方法及其治疗用途 |
WO2013061205A2 (fr) | 2011-10-26 | 2013-05-02 | Pfizer Limited | Composés chimiques |
GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
EP2788332A1 (fr) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques |
EP2606726A1 (fr) | 2011-12-21 | 2013-06-26 | Bayer CropScience AG | Dérivés de trifluoroéthylsulfure substitués par du N-arylamidine en tant qu'acaricides et insecticides |
CN104125953A (zh) | 2011-12-23 | 2014-10-29 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
US9403839B2 (en) | 2012-01-16 | 2016-08-02 | Vertex Pharmaceuticals Incorporated | Pyran-spirocyclic piperidine amides as modulators of ion channels |
WO2013114250A1 (fr) | 2012-02-03 | 2013-08-08 | Pfizer Inc. | Dérivés d'imidazopyridine et de benziimidazole en tant que modulateurs du canal sodium |
WO2013131018A1 (fr) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Inhibiteurs biaryle du canal sodique |
US8481479B1 (en) | 2012-03-07 | 2013-07-09 | Shaker A. Mousa | Formulations of factor VIIa inhibitors and utility |
US8980823B2 (en) | 2012-03-07 | 2015-03-17 | Shaker A. Mousa | Formulations of Factor VIIa inhibitors and utility |
US20150210717A1 (en) | 2012-09-13 | 2015-07-30 | Baden-Württemberg Stiftung Gmbh | Specific inhibitors of protein p21 as therapeutic agents |
WO2014055634A1 (fr) | 2012-10-02 | 2014-04-10 | Yale University | Identification de petites molécules inhibitrices d'histone déméthylase à de domaine jumonji 1a (jarid1a) et 1b (jarid1b) interactif riche en at, |
US9216180B2 (en) | 2012-10-02 | 2015-12-22 | New York University | Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay |
US20140200215A1 (en) | 2013-01-15 | 2014-07-17 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
SI3239134T1 (sl) | 2013-01-31 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Piridon amidi kot modulatorji natrijevih kanalov |
JP6346622B2 (ja) | 2013-01-31 | 2018-06-20 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ナトリウムチャネルの調節剤としてのアミド |
WO2014120815A1 (fr) | 2013-01-31 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Quinoléine et quinazoline amides comme modulateurs des canaux sodiques |
CN103961348B (zh) | 2013-02-05 | 2016-08-17 | 上海交通大学医学院 | Senp1小分子抑制剂及其应用 |
WO2014134127A1 (fr) | 2013-02-26 | 2014-09-04 | Northeastern University | Nitro-esters cannabinergiques et analogues associés |
WO2014149207A2 (fr) | 2013-03-15 | 2014-09-25 | Dow Agrosciences Llc | Compositions insecticides à base de benzimidazole et procédés apparentés |
JP5902641B2 (ja) | 2013-03-27 | 2016-04-13 | 富士フイルム株式会社 | 光干渉顔料およびその製造方法 |
JP2014232188A (ja) | 2013-05-29 | 2014-12-11 | コニカミノルタ株式会社 | セルロースアシレートフィルム、円偏光板及び画像表示装置 |
WO2014192681A1 (fr) | 2013-05-31 | 2014-12-04 | コニカミノルタ株式会社 | Composition de résine, élément optique, film optique, plaque de polarisation, plaque de polarisation circulaire et dispositif d'affichage d'image |
WO2015030898A2 (fr) | 2013-06-07 | 2015-03-05 | The Regents Of The University Of California | Commutateurs résonants micromécaniques et pompes de charge |
EP3010512B1 (fr) | 2013-06-18 | 2017-12-27 | Merck Sharp & Dohme Corp. | Dérivés de nucléosides cycliques à substitution phosphonate et leurs méthodes d'utilisation pour le traitement de maladies virales |
CA2917767C (fr) | 2013-07-12 | 2022-05-03 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | Cystobactamides |
HUE037876T2 (hu) | 2013-07-19 | 2018-09-28 | Vertex Pharma | Szulfonamidok mint nátriumcsatorna-modulátorok |
CN105611924A (zh) | 2013-07-25 | 2016-05-25 | 泰莱托恩基金会 | Fapp2的抑制剂及其用途 |
EP3027590A1 (fr) | 2013-07-31 | 2016-06-08 | Minoryx Therapeutics S.L. | Di(hétéro)arylamides et sulfonamides, procédés permettant leur préparation et utilisations thérapeutiques de ceux-ci |
KR101628288B1 (ko) | 2013-09-30 | 2016-06-08 | 주식회사 엘지화학 | 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체 |
WO2015085238A1 (fr) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibiteurs de lpxc |
SG10201913313QA (en) | 2013-12-13 | 2020-03-30 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
US9204150B2 (en) | 2014-02-26 | 2015-12-01 | Intel Corporation | Techniques for evaluating compressed motion video quality |
US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
WO2016022626A1 (fr) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antagonistes hétérocycliques des récepteurs cgrp |
WO2016040449A1 (fr) | 2014-09-10 | 2016-03-17 | Raze Therapeutics, Inc. | Inhibiteurs de la 3-phosphoglycérate déshydrogénase) et leurs utilisations |
EP2997966A1 (fr) | 2014-09-16 | 2016-03-23 | Sanofi | Dérivés de pyrrolidine sulfonamide naphtyle en tant que modulateurs KEAP-1 pour le traitement du diabète, l'obésité, de la dyslipidémie et de troubles apparentés |
CN106317027A (zh) | 2015-06-15 | 2017-01-11 | 山东轩竹医药科技有限公司 | 杂芳基酰胺类衍生物及其作为tgr5激动剂的应用 |
EP3350181B1 (fr) | 2015-09-02 | 2023-11-01 | The Regents of The University of California | Ligands her3 et utilisations de ceux-ci |
US11413278B2 (en) | 2015-10-08 | 2022-08-16 | The Regents Of The University Of California | Compounds and methods for promoting stress resistance |
CA3001857A1 (fr) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Composes, compositions et methodes d'utilisation contre des granules de stress |
WO2017161028A1 (fr) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Inhibiteurs substitués de ménine-mll et méthodes d'utilisation |
EP3519533B1 (fr) | 2016-09-28 | 2020-12-16 | Merck Patent GmbH | Matériau polymérisable à cristaux liquides et film polymérisé à cristaux liquides |
JP2020500207A (ja) | 2016-09-28 | 2020-01-09 | ブレード・セラピューティクス・インコーポレイテッド | カルパインモジュレーター及びそれらの治療上の使用 |
WO2018161033A1 (fr) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Inhibiteurs ire1-alpha à petites molécules |
MX2019012532A (es) | 2017-04-20 | 2019-12-02 | Univ California | Moduladores de k-ras. |
WO2018202681A1 (fr) | 2017-05-04 | 2018-11-08 | Bayer Cropscience Aktiengesellschaft | Utilisation de benzènes disubstitués pour lutter contre des organismes nuisibles résistants aux insecticides |
JP2019015998A (ja) | 2017-07-03 | 2019-01-31 | 東芝テック株式会社 | 情報処理装置およびプログラム |
JP7277431B2 (ja) | 2017-07-11 | 2023-05-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのカルボキサミド |
WO2019018119A1 (fr) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | Méthodes de traitement de l'épilepsie et d'affections associées à kcnti |
CN111163766A (zh) | 2017-08-17 | 2020-05-15 | 医肯纳肿瘤学公司 | Ahr抑制剂和其用途 |
MX2020007562A (es) | 2018-01-30 | 2020-09-03 | Pi Industries Ltd | Nuevas antranilamidas, su uso como insecticida y procesos para su preparacion. |
AU2019218387A1 (en) | 2018-02-12 | 2020-08-27 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
TW202003591A (zh) | 2018-04-27 | 2020-01-16 | 德商馬克專利公司 | 可聚合的液晶材料及經聚合的液晶膜 |
KR20210005160A (ko) | 2018-04-27 | 2021-01-13 | 메르크 파텐트 게엠베하 | 중합성 액정 물질 및 중합된 액정 필름 |
WO2019241787A1 (fr) | 2018-06-15 | 2019-12-19 | The Regents Of The University Of Colorado A Body Corporate | Nouveaux inhibiteurs cycliques de la gmp-amp synthase (cgaz) et leur procédé d'utilisation |
WO2020051207A2 (fr) | 2018-09-04 | 2020-03-12 | Magenta Therapeutics Inc. | Antagonistes du récepteur de l'aryl-hydrocarbone et procédés d'utilisation de ces derniers |
WO2020081572A1 (fr) | 2018-10-15 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs du facteur de transcription à domaine associé transcriptionnel amélioré (tead) et leurs utilisations |
WO2020123675A1 (fr) | 2018-12-11 | 2020-06-18 | Duke University | Compositions et procédés pour le traitement du cancer |
CA3124970A1 (fr) | 2018-12-28 | 2020-07-02 | Cedars-Sinai Medical Center | Methodes de traitement de maladies intestinales inflammatoires ciblant la ripk2 |
US20220110923A1 (en) | 2019-01-10 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
WO2020146682A1 (fr) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides utilisés en tant que modulateurs de canaux sodiques |
EP3914669A1 (fr) | 2019-01-22 | 2021-12-01 | Merck Patent GmbH | Procédé de préparation d'un film polymère à cristaux liquides |
WO2020159576A1 (fr) | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Activateurs de la mitofusine et leurs procédés d'utilisation |
WO2020176763A1 (fr) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8 |
AU2020241258A1 (en) | 2019-03-15 | 2021-10-07 | The General Hospital Corporation | Novel small molecule inhibitors of tead transcription factors |
US20220218632A1 (en) | 2019-03-28 | 2022-07-14 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
WO2020219867A1 (fr) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur |
KR20220019234A (ko) | 2019-04-30 | 2022-02-16 | 메르크 파텐트 게엠베하 | 반응성 메소젠 |
US20220324880A1 (en) | 2019-06-10 | 2022-10-13 | Kymara Therapeutics, Inc. | Smarca inhibitors and uses thereof |
-
2018
- 2018-07-11 JP JP2020501369A patent/JP7277431B2/ja active Active
- 2018-07-11 BR BR112020000553-3A patent/BR112020000553A2/pt not_active Application Discontinuation
- 2018-07-11 US US16/032,799 patent/US10647661B2/en active Active
- 2018-07-11 CA CA3069720A patent/CA3069720A1/fr not_active Abandoned
- 2018-07-11 PE PE2020000022A patent/PE20201164A1/es unknown
- 2018-07-11 TN TNP/2020/000001A patent/TN2020000001A1/en unknown
- 2018-07-11 SG SG11202000230VA patent/SG11202000230VA/en unknown
- 2018-07-11 EP EP18746526.5A patent/EP3651752A1/fr active Pending
- 2018-07-11 WO PCT/US2018/041649 patent/WO2019014352A1/fr unknown
- 2018-07-11 UY UY0001037806A patent/UY37806A/es not_active Application Discontinuation
- 2018-07-11 MA MA049566A patent/MA49566A/fr unknown
- 2018-07-11 TW TW107123989A patent/TW201920081A/zh unknown
- 2018-07-11 JO JOP/2020/0001A patent/JOP20200001A1/ar unknown
- 2018-07-11 AU AU2018300150A patent/AU2018300150A1/en not_active Abandoned
- 2018-07-11 CR CR20200064A patent/CR20200064A/es unknown
- 2018-07-11 KR KR1020207003933A patent/KR20200026987A/ko unknown
- 2018-07-11 CN CN201880058540.1A patent/CN111065383A/zh active Pending
-
2020
- 2020-01-08 CO CONC2020/0000145A patent/CO2020000145A2/es unknown
- 2020-01-08 PH PH12020500066A patent/PH12020500066A1/en unknown
- 2020-01-08 DO DO2020000004A patent/DOP2020000004A/es unknown
- 2020-01-09 IL IL271948A patent/IL271948A/en unknown
- 2020-01-10 CL CL2020000075A patent/CL2020000075A1/es unknown
- 2020-01-15 EC ECSENADI20203147A patent/ECSP20003147A/es unknown
- 2020-03-19 US US16/824,255 patent/US11603351B2/en active Active
-
2022
- 2022-12-13 US US18/065,208 patent/US20230286907A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7277431B2 (ja) | 2023-05-19 |
CO2020000145A2 (es) | 2020-01-17 |
CN111065383A (zh) | 2020-04-24 |
CL2020000075A1 (es) | 2020-07-31 |
IL271948A (en) | 2020-02-27 |
JOP20200001A1 (ar) | 2022-10-30 |
UY37806A (es) | 2020-01-31 |
US20230286907A1 (en) | 2023-09-14 |
DOP2020000004A (es) | 2020-07-15 |
US10647661B2 (en) | 2020-05-12 |
EP3651752A1 (fr) | 2020-05-20 |
ECSP20003147A (es) | 2020-02-28 |
CR20200064A (es) | 2020-08-03 |
KR20200026987A (ko) | 2020-03-11 |
JP2020526561A (ja) | 2020-08-31 |
CA3069720A1 (fr) | 2019-01-17 |
US11603351B2 (en) | 2023-03-14 |
US20210094906A1 (en) | 2021-04-01 |
BR112020000553A2 (pt) | 2020-07-21 |
AU2018300150A1 (en) | 2020-01-30 |
TN2020000001A1 (en) | 2021-10-04 |
WO2019014352A1 (fr) | 2019-01-17 |
MA49566A (fr) | 2020-05-20 |
PE20201164A1 (es) | 2020-10-28 |
TW201920081A (zh) | 2019-06-01 |
PH12020500066A1 (en) | 2020-09-28 |
US20190016671A1 (en) | 2019-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL271948A (en) | Carboxamides as modulators of sodium channels | |
IL283582A (en) | ror - gamma modulators | |
HK1256599A1 (zh) | ROR-γ的調節劑 | |
HK1255699A1 (zh) | Kras表達的調節劑 | |
HK1217692A1 (zh) | 作為鈉通道調節劑的醯胺 | |
HK1223604A1 (zh) | 用作鈉通道調節劑的磺醯胺類 | |
GB201609764D0 (en) | 3D printing of gel networks | |
IL259762B (en) | Complement activity modulators | |
HK1246672A1 (zh) | 補體活性的調節劑 | |
IL281492A (en) | Modulators of PNPLA3 expression | |
EP3364974A4 (fr) | Modulateurs de maladies impliquant des télomères | |
IL283967A (en) | Modulators of hsd17b13 expression | |
IL304618A (en) | Modulators of pcsk9 expression | |
PT3334734T (pt) | Forma c de avibactam sódico | |
AU2015901096A0 (en) | Sodium channel modulators |